Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Upstream Bio (UPB) EBT (2023 - 2025)

Historic EBT for Upstream Bio (UPB) over the last 3 years, with Q3 2025 value amounting to -$33.7 million.

  • Upstream Bio's EBT fell 11095.13% to -$33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$122.2 million, marking a year-over-year decrease of 11352.39%. This contributed to the annual value of -$65.6 million for FY2024, which is 8259.48% down from last year.
  • As of Q3 2025, Upstream Bio's EBT stood at -$33.7 million, which was down 11095.13% from -$39.9 million recorded in Q2 2025.
  • In the past 5 years, Upstream Bio's EBT registered a high of -$7.9 million during Q3 2023, and its lowest value of -$39.9 million during Q2 2025.
  • Moreover, its 3-year median value for EBT was -$16.0 million (2024), whereas its average is -$20.8 million.
  • As far as peak fluctuations go, Upstream Bio's EBT tumbled by 6581.06% in 2024, and later plummeted by 17222.26% in 2025.
  • Upstream Bio's EBT (Quarter) stood at -$12.8 million in 2023, then plummeted by 65.81% to -$21.2 million in 2024, then tumbled by 58.78% to -$33.7 million in 2025.
  • Its last three reported values are -$33.7 million in Q3 2025, -$39.9 million for Q2 2025, and -$27.3 million during Q1 2025.